

Special Issue

Breast Cancer: Clinical Trial and Translational Research

Message from the Guest Editors

Researchers discover the seeds of new medical technologies and treatments in basic research. Translational research refers to research conducted with the aim of commercializing these seeds of medicine into new medical technologies and drugs that can be used in actual medical institutions. Therefore, it covers a wide range of areas from preclinical to clinical development, including not only therapeutic drugs but also technologies for detecting breast cancer, assisting surgery, and so on. In this SPECIAL EDITION, we hope that you will publish data that are in the process of proving excellent technology, in a state that is about to go from the lab to the clinic. We look forward to receiving submissions from many of you.

Guest Editors

Dr. Hirokazu Tanino
Dr. Masayuki Nagahashi
Dr. Akari Murakami

Deadline for manuscript submissions

closed (23 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/132683

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)